A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017

Phase 1 Not yet recruiting 40 enrolled Luye Pharma Group Ltd.

RandomizedSequentialQuadruple-blindTreatment

Summary

This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects

Timeline

Start: 2025-05
Primary completion: 2025-10
Completion: 2025-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY03017	Unknown	10 mg	Oral
Subject	LY03017	Unknown	40 mg	Oral

Indications

No indication recorded.